1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62233810A3D140321852582B9006F6C16
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/2233810A3D140321852582B9006F6C16!OpenDocument
18
19OpenDocument
2018.206.48.243
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Data Management and Biostatics

Document Excerpt: Understanding the Changing Landscape of Real World Evidence Generation: Economic/Reimbursement Studies and RWE Budget

DB Image

ID: MD-616


Features:

13 Info Graphics

6 Data Graphics

150 Metrics


Pages/Slides: 4


Published: 2018


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
To download this excerpt, click "Download Free Excerpt" on the right.


To return to the study abstract to purchase the full study - click here.

This excerpt includes research findings and metrics from document #5516 "Understanding the Changing Landscape of Real World Evidence Generation: Economic/Reimbursement Studies and RWE Budget"


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Manufacturing; Biotech; Consumer Products; Medical Device; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Abbott; Abbvie; Bayer; Johnson & Johnson; Allergan; AstraZeneca; Celldex Therapeutics; Dermira; EMD Serono; Flexion; GlaxoSmithKline ; Grifols; Janssen; Novartis; Genzyme; Merck; UCB Pharma; Vifor Pharma; Sanofi

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.